10 unknown, 2 not yet recruiting, 1 completed, 1 recruiting. 12 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Unknown 9, Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow HLX07: new trials by email Literature Review of HLX07 trials Research Report on HLX07
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer HLX07, HLX07 placebo, Serplulimab - Squamous NSCLC | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 720 | 2026-03-01 | 2026-01-06 |
| A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer HLX43 dose 1 + HLX07, HLX43 dose 2 + HLX07, HLX43 dose 3 + Serplulimab - Colon Cancer Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Henlius Biotech | 126 | 2026-01-31 | 2026-01-22 |
| A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3 - Carcinoma of Head and/or Neck | Phase 2 | Recruiting | Shanghai Henlius Biotech | 167 | 2025-04-22 | 2026-03-05 |
| HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors HLX07 - Solid Tumor | Phase 1 | Unknown | Shanghai Henlius Biotech | 24 | 2023-03-30 | 2022-05-05 |
| A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer HLX07, HLX10, carboplatin and etoposide - Small-cell Lung Cancer | Phase 2 | Unknown | Shanghai Henlius Biotech | 20 | 2023-03-29 | 2022-05-04 |
| A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression HLX07+carboplatin+pemetrexed, HLX07+docetaxel, HLX07 - HLX07, nsqNSCLC, High EGFR Expression | Phase 2 | Unknown | Shanghai Henlius Biotech | 60 | 2023-02-01 | 2022-07-06 |
| Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC HLX07, HLX10, placebo - Nasopharyngeal Carcinoma by AJCC V8 Stage | Phase 2 | Unknown | Shanghai Henlius Biotech | 75 | 2022-12-14 | 2024-06-17 |
| A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC HLX07+HLX10+ Cisplatin+5-FU, HLX07 - ESCC or Esophageal Adenosquamous Carcinoma | Phase 2 | Unknown | Shanghai Henlius Biotech | 60 | 2022-08-25 | 2022-08-29 |
| HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma HLX07, HLX10, HLX04 - Advanced Hepatocellular Carcinoma | Phase 2 | Unknown | Shanghai Henlius Biotech | 60 | 2022-08-01 | 2022-05-03 |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC HLX07, HLX10, mFOLFOX6 - CRC | Phase 2 | Unknown | Shanghai Henlius Biotech | 50 | 2022-07-15 | 2022-05-03 |
| The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) HLX07 - Cutaneous Squamous Cell Carcinoma | Phase 2 | Unknown | Shanghai Henlius Biotech | 20 | 2022-06-15 | 2022-06-21 |
| HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer HLX07+HLX10+oxaliplatin+capecitabine, HLX07 - Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) | Phase 2 | Unknown | Shanghai Henlius Biotech | 40 | 2022-03-23 | 2022-05-02 |
| Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors HLX10, HLX07, HLX07 placebo - Head and Neck Squamous Cell Carcinoma | Phase 2 | Unknown | Shanghai Henlius Biotech | 131 | 2020-07-29 | 2023-08-08 |
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers HLX07, Acetaminophen, dexamethasone - Solid Tumour | Phase 1 | Completed | Henlix, Inc | 19 | 2016-09-01 | 2019-07-30 |
Colonic Neoplasms (1) · Neoplasm Metastasis (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Shanghai Henlius Biotech (13) · Henlix, Inc (1)
China (11) · Taiwan (1) · United States (1)
Chaosu Hu, Dr (1) · Dongmei Ji (1) · Guangyuan Hu (1) · Guochun Cao (1) · Jinming Yu (1) · Man Hu, Dr (1) · Meiyu Fang (1) · Peng Junjie (1) · Qingyuan Zhang (1) · Shubin Wang (1) · Wei Wang (1) · Weidong Jiang, Ph.D. (1) · Xiaohui He (1) · Yan Sun (1) · Ye Guo, PhD (1)